Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01953211 · ClinicalTrials.gov registry record
Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity
A clinical trial of Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy, sponsored by University of Southern California.
- Completed
- Registry status
- 64
- Enrollment target
- 1
- Study location
NCT01953211: Completed study of Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy, sponsored by University of Southern California.
NCT01953211 is a study of Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy that has completed, run by University of Southern California. The registered enrollment target is 64 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01953211, a study of Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
The degree of suppression and subsequent activation of the hypothalamic-pituitary-ovarian axis during the hormone-free interval in combined oral contraceptive (COC) hormone users varies depending on the dose of ethinyl estradiol in the formulation. This variation in activation may be associated with different side effects during the hormone free interval. Progesterone (P) remained suppressed during all 6 COC regimens (\<1.8 ng/mL), which indicates continuous contraceptive efficacy during the 7-day hormone free interval of all formulations studied.
Primary Outcome
mean FSH on day 7 of the pill free interval
Conditions Studied
Interventions
- DRUG combined oral contraceptives
Study Locations (1)
California
- LAC and USC Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
What the finished NCT01953211 record still lists
NCT01953211 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target.
The record links to 1 condition, with Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy appearing as the primary indexed condition, and to 1 intervention - of which combined oral contraceptives is the first listed.
NCT01953211 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01953211 about?
NCT01953211 is a clinical study titled "Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity". The degree of suppression and subsequent activation of the hypothalamic-pituitary-ovarian axis during the hormone-free interval in combined oral contraceptive (COC) hormone users varies depending on the dose of ethinyl estradiol in the formulation. This variation in activation may be associated with...
What is the current status of trial NCT01953211?
This trial is currently completed. The enrollment target is 64 participants.
What conditions does trial NCT01953211 study?
This clinical trial studies the following conditions: Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy.
What interventions are being tested in trial NCT01953211?
The interventions under investigation include: combined oral contraceptives (DRUG).
Who is sponsoring clinical trial NCT01953211?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01953211 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins